Does anyone think it is more probable that Bisantrene somehow loses its world leading FTO inhibitory properties and improves its failed topo2 inhibitory properties (anthracycline) when it is injected into humans to function against cancer?
Seriously.
As far as cardioprotection is concerned, I have no idea, but it's not FTO. Win for us.
Does anyone think it is more probable that Bisantrene somehow...
-
- There are more pages in this discussion • 4,475 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.73 |
Change
0.075(4.53%) |
Mkt cap ! $294.8M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.73 | $1.64 | $271.9K | 161.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.73 | 3844 | 2 |
View Market Depth
| Last trade - 16.10pm 20/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |